# About Tesamorelin Reviews: An Independent Literature Digest

> Tesamorelin Reviews is an independent editorial project summarizing the peer-reviewed tesamorelin literature as a reading console. Not a clinic, not a vendor — editorial commentary on published science.

Who publishes this digest, what "reviews" means here, and what this site is not.

## What this site is

Tesamorelin Reviews is an independent editorial project that publishes summaries of the peer-reviewed research literature on tesamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site reads the published record as a console: each peer-reviewed trial becomes a panel — population, dose, route, outcome, citation — with the FDA-approval scope surfaced as the first status flag and the honest data gaps left visible rather than papered over.

## How we review the tesamorelin literature

"Reviews" here means peer-reviewed-literature review, not product reviews. There are no tesamorelin reviews of vendors, no ratings, no prices, and nothing for sale on this site. Each finding is read against its source study and tagged by the strength of its evidence: established human-trial findings (the NEJM, AIDS, JAMA and Lancet HIV trials), healthy-cohort and pharmacokinetic data, and clearly marked off-label gaps where no large randomized trial exists.

The composed lens is recent-research, so the newest panels are lit first — the 2026 five-trial meta-analysis, the 2024 integrase-inhibitor-era trial, and the 2025 cognition trial whose neurocognitive result was honestly null — while the pivotal 2007 and 2008 trials hold as the established baseline. We surface what the studies measured, and we say plainly where the data stops.

## What the name means

The "reviews" in the domain is editorial framing — the position this publisher occupies relative to the literature, reviewing each study as a panel in a reading console. It is not a claim that the site offers consultation, treatment, or prescription services, and it is not a directory of sellers. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; research-grade material is supplied for laboratory research and is not an approved finished medicine to self-administer. Nothing on this site is a recommendation to use it.

---

A trial console on a dark field — the tesamorelin record read newest panel first, the FDA-approved-for-HIV-lipodystrophy scope flagged before any number and the off-label edge held lit; no clinic at this console and nothing here dosed, dispensed, or sold.